Loading organizations...
§ Private Profile · Shenzhen, Guangdong, China
Biotechnology company researching and developing targeted anti-tumor drugs for oncology, focused on small molecule-drug conjugates.
Ascentawits Pharmaceuticals is a clinical-stage biotechnology company that develops small molecule-drug conjugates for targeted cancer therapies, based in Shenzhen, China. The pre-commercial enterprise focuses on precision oncology treatments designed to enhance tumor cell penetration and deliver therapeutic agents directly to malignant solid neoplasms and digestive system disorders. Operating at the Series B funding stage, the organization has filed more than 200 patents globally and secured over 50 granted patents for its proprietary molecular designs. The company collaborates with industry partners like OBI Pharma to advance its lead candidate, AST-3424, which recently presented interim Phase II clinical trial results at the Chinese Society of Clinical Oncology meeting. Recognized as a specialized and sophisticated enterprise by the Shenzhen municipal government, the firm continues advancing its broader pharmaceutical pipeline. Ascentawits Pharmaceuticals was founded in 2014 by Jian Xin Duan.
Ascentawits has raised $29.8M across 2 funding rounds.
Ascentawits has raised $29.8M in total across 2 funding rounds.
Ascentawits has raised $29.8M across 2 funding rounds. Most recently, it raised $15.5M Pre-Series B in February 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 11, 2021 | $15.5M Series A Plus | — | Sangel Capital | Announced |
| Feb 28, 2020 | $14.3M Series A | Guozhong Capital | — | Announced |
Ascentawits has raised $29.8M in total across 2 funding rounds.
Ascentawits's investors include Sangel Capital, Guozhong Capital.